Quarterly ResultMay 7, 2026, 07:08 AM
Ligand Q1 Royalty Revenue +56%; Reaffirms 2026 Guidance with XOMA
AI Summary
Ligand Pharmaceuticals reported strong first quarter 2026 financial results, with royalty revenue increasing 56% year-over-year to $43.0 million and total revenues growing 14% to $51.7 million. The company reaffirmed its previously raised 2026 full-year financial guidance, which incorporates the anticipated partial-year contribution from the pending acquisition of XOMA Royalty Corporation. Key corporate developments include the definitive agreement to acquire XOMA for $39.00 per share and the full FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS).
Key Highlights
- Ligand to acquire XOMA Royalty for $39.00 per share, expected to close Q3 2026.
- Q1 2026 Royalty Revenue: $43.0 million, up 56% year-over-year.
- Q1 2026 Total Revenues: $51.7 million, up 14% year-over-year.
- Q1 2026 Adjusted Net Income: $34.6 million, or $1.63 per diluted share, up 30%.
- Reaffirmed 2026 full-year adjusted EPS guidance: $8.50 to $9.50.
- Reaffirmed 2026 full-year royalty revenue guidance: $225 million to $250 million.
- FDA approved Filspari for FSGS on April 13, 2026, expanding its indication.
- Cash, cash equivalents, and short-term investments totaled $779.4 million as of March 31, 2026.